Updated Patent Situation on Key Products for Hepatitis C Treatment in Asia – August 2015

Updated Patent Situation on Key Products for Hepatitis C Treatment in Asia – August 2015

A summarized information of patents on sofosbuvir, ledipasvir and daclatasvir in parts of South and south-east Asia. The documents also covers situation of registration of these medications in the countries as on August 2015..read full document

/ News

Share the Post

Related Posts

Fact Sheet Hepatitis B
IAC a community group in Indonesia demanding national food and drugs authority to expedite registration process of DAA medicines in Indonesia
Asia-Pacific Aids Groups Express Deep Dismay At Conclusion Of Secretly Negotiated Trans-Pacific Partnership Agreement That Threatens Future Access To Affordable Generic Medicines And Sustainable Development Goals
Strategies to Secure Access to Generic HCV Medicines
Patient Groups and CSOs in Asia written a letter to Indian Government to Request Waiver on Local Clinical Trial for The Coming Generic DAAs
20 YEARS AFTER THE TRIPS AGREEMENT, U.S. GOVERNMENT SCORES MASSIVE VICTORY FOR BIG PHARMA IN TPP DEAL
Read More
Story from Ajitshwor Wangkheirakpam, Manipur, India
Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C